Akili, Inc. (the company or Akili) announced as previously disclosed by the company on May 29, 2024, the company entered into an Agreement and Plan of Merger, dated as of May 29, 2024 (the Merger Agreement) with Virtual Therapeutics Corporation and Alpha Merger Sub, Inc. (Purchaser). Pursuant to the terms of the Merger Agreement, at the Effective Time, each of Matthew Franklin, Adam Gazzaley, M.D., Ph.D., Mary Hentges, William ?BJ? Jones, Jr., Christine Lemke, W. Edward Martucci II, Ph.D., and John Spinale resigned from the board of directors of the company.

These resignations were tendered in connection with the Merger and not as a result of any disagreements between the company and the resigning individuals on any matters related to the company?s operations, policies, or practices. Following the Merger and pursuant to the terms of the Merger Agreement, immediately following the Effective Time, the directors and officers of Purchaser immediately prior to the Effective Time became the directors and officers of the Surviving Corporation. The sole director of Purchaser immediately prior to the Effective Time was Daniel J. Elenbaas.

The executive officers of Purchaser immediately prior to the Effective Time were Daniel J. Elenbaas, serving as President, and Matt McIntire, serving as Treasurer and Secretary.